Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HIMX | -49.68% | $1.26B | +21.62% | 3.64% |
LQDT | -48.50% | $1.06B | +102.28% | 0.00% |
CIEN | -18.43% | $11.86B | +65.05% | 0.00% |
HUSA | -17.13% | $21.33M | 0.00% | 0.00% |
WBD | -15.91% | $23.87B | -5.99% | 0.00% |
ACI | -15.02% | $12.01B | -7.00% | 2.32% |
KO | -13.96% | $267.26B | +3.42% | 3.11% |
HSY | -11.66% | $31.43B | -18.91% | 3.52% |
PRPO | -11.30% | $8.98M | +14.99% | 0.00% |
MNR | -10.47% | $1.82B | +3.73% | 18.10% |
CGNT | -10.20% | $631.96M | +52.87% | 0.00% |
GIS | -10.15% | $32.40B | -6.45% | 4.06% |
NTNX | -8.85% | $16.89B | +25.15% | 0.00% |
CHRW | -8.51% | $12.16B | +19.85% | 2.36% |
DDD | -8.49% | $410.93M | -37.65% | 0.00% |
PEP | -8.32% | $198.87B | -12.77% | 3.67% |
BSM | -8.06% | $3.19B | -6.07% | 10.54% |
KDP | -7.90% | $42.24B | -2.17% | 2.86% |
HIHO | -7.83% | $8.50M | -5.62% | 6.22% |
CVM | -7.80% | $29.96M | -83.87% | 0.00% |
Finnhub
LEXINGTON, Mass., Jan. 15, 2025 -- Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of...
Finnhub
NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. . Such investors are advised to contact Danielle Peyton at...
Finnhub
Duality Biologics and GSK enter into an exclusive option agreement to exploit gastrointestinal cancer target, DB-1324On December 4, 2024, Duality Biologics , a clinical-stage biotech company focusing...
SeekingAlpha
Keros Therapeutics' stock faces safety concerns but offers favorable risk-reward for a rebound, trading undervalued at essentially cash value. Explore more details here.
SeekingAlpha
Keros Therapeutics is a clinical-stage biopharmaceutical company focusing on rare and hematological diseases. Read why I rate KROS stock a Hold now.
Yahoo
Wells Fargo raised the firm’s price target on Keros Therapeutics (KROS) to $28 from $11 and keeps an Overweight rating on the shares. The safety findings announced in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension, “basically zeroed expectations,” though cash plus pipeline is worth more than where the stock is right now, the analyst tells investors in a research note. Published first on The
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LOVE | 55.02% | $412.06M | +19.78% | 0.00% |
RYN | 38.38% | $3.85B | -18.47% | 4.31% |
NDSN | 37.93% | $11.83B | -17.21% | 1.39% |
ADBE | 37.00% | $181.67B | -30.95% | 0.00% |
AGIO | 35.42% | $1.90B | +51.87% | 0.00% |
ARVN | 35.12% | $1.18B | -54.80% | 0.00% |
OXM | 33.98% | $1.35B | -10.69% | 3.00% |
ORA | 33.98% | $4.00B | -1.40% | 0.70% |
FTAI | 33.49% | $15.72B | +218.03% | 0.75% |
SFIX | 32.95% | $611.38M | +51.57% | 0.00% |
PLAY | 31.57% | $971.81M | -48.74% | 0.00% |
CRNX | 30.46% | $3.30B | -4.50% | 0.00% |
IDYA | 30.02% | $1.97B | -43.88% | 0.00% |
AKRO | 29.84% | $1.53B | -0.73% | 0.00% |
KYMR | 29.62% | $2.60B | +42.22% | 0.00% |
ENTA | 29.43% | $102.58M | -57.02% | 0.00% |
SNDX | 29.26% | $1.08B | -43.65% | 0.00% |
FATE | 29.14% | $142.94M | -72.17% | 0.00% |
OCUL | 28.48% | $1.24B | +87.14% | 0.00% |
CHRS | 28.40% | $165.91M | -38.72% | 0.00% |
Current Value
$9.961 Year Return
Current Value
$9.961 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ENR | <0.01% | $2.51B | +10.07% | 3.40% |
E | 0.02% | $45.13B | -12.52% | 7.26% |
TK | -0.02% | $711.73M | +10.59% | 0.00% |
CHE | 0.03% | $8.00B | -9.55% | 0.33% |
VTMX | 0.05% | $2.12B | -36.04% | 2.99% |
KVUE | 0.05% | $40.32B | -0.94% | 3.83% |
CIVI | 0.06% | $5.17B | -12.59% | 3.68% |
EC | 0.08% | $17.62B | -27.19% | 18.27% |
EOG | -0.09% | $76.36B | +21.07% | 2.67% |
STVN | -0.12% | $5.90B | -23.17% | 0.26% |
WEC | 0.12% | $29.92B | +14.55% | 3.51% |
BRBR | 0.13% | $9.37B | +34.67% | 0.00% |
MO | -0.16% | $87.05B | +25.36% | 7.84% |
MCK | -0.17% | $75.37B | +21.54% | 0.45% |
ES | -0.18% | $20.51B | -0.46% | 5.03% |
MNOV | -0.18% | $93.68M | +25.66% | 0.00% |
HRL | -0.19% | $16.48B | -4.18% | 3.77% |
RDWR | -0.23% | $882.96M | +25.70% | 0.00% |
CB | -0.24% | $107.03B | +16.59% | 1.34% |
ASPS | -0.24% | $19.06M | -72.55% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DRLL | -0.03% | $318.59M | 0.41% |
WEAT | -0.08% | $121.69M | 0.28% |
CMDY | 0.10% | $292.72M | 0.28% |
IYE | 0.12% | $1.33B | 0.39% |
IVOL | -0.19% | $450.97M | 1.02% |
XLE | 0.27% | $33.71B | 0.09% |
FENY | 0.47% | $1.55B | 0.084% |
FLTR | 0.49% | $1.97B | 0.14% |
BILZ | -0.54% | $616.87M | 0.14% |
VDE | 0.61% | $7.86B | 0.1% |
MINT | -0.62% | $12.01B | 0.35% |
RSPG | 1.02% | $549.42M | 0.4% |
BCI | -1.14% | $1.36B | 0.26% |
DBA | -1.19% | $812.87M | 0.93% |
KLIP | 1.30% | $120.94M | 0.93% |
IXC | 1.38% | $1.97B | 0.41% |
FCG | 1.48% | $445.24M | 0.6% |
HYZD | 1.64% | $165.79M | 0.43% |
XLP | 1.69% | $15.91B | 0.09% |
IBMN | 1.70% | $484.21M | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
UNG | -14.33% | $820.81M | 1.06% |
DBE | -12.39% | $50.63M | 0.77% |
AGZD | -11.64% | $142.77M | 0.23% |
KCCA | -10.80% | $116.67M | 0.87% |
VIXY | -10.36% | $195.31M | 0.85% |
CTA | -10.09% | $536.34M | 0.76% |
UUP | -9.76% | $640.67M | 0.77% |
GSG | -9.02% | $1.07B | 0.75% |
DBO | -8.85% | $228.06M | 0.77% |
COMT | -7.00% | $717.70M | 0.48% |
USDU | -7.00% | $390.63M | 0.5% |
TAIL | -5.91% | $65.48M | 0.59% |
USCI | -4.98% | $200.39M | 1.07% |
DBC | -4.86% | $1.35B | 0.87% |
PDBC | -4.60% | $4.29B | 0.59% |
CCOR | -4.02% | $82.35M | 1.18% |
SHYD | -3.61% | $310.85M | 0.35% |
TPMN | -3.03% | $41.70M | 0.65% |
FTXG | -2.22% | $22.19M | 0.6% |
FTGC | -2.12% | $2.33B | 1.02% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 41.15% | $268.92M | 0% |
XBI | 38.50% | $6.18B | 0.35% |
PTH | 36.05% | $117.64M | 0.6% |
IBB | 32.93% | $6.41B | 0.45% |
ARKG | 31.75% | $1.09B | 0.75% |
IWC | 31.16% | $927.11M | 0.6% |
IWO | 30.58% | $12.47B | 0.24% |
PINK | 30.54% | $139.16M | 0.5% |
GNOM | 30.53% | $68.90M | 0.5% |
XPH | 30.14% | $155.81M | 0.35% |
FBT | 29.13% | $1.17B | 0.56% |
VTWO | 28.41% | $12.12B | 0.1% |
IWM | 28.12% | $70.21B | 0.19% |
PBE | 27.47% | $255.43M | 0.58% |
PRFZ | 27.05% | $2.51B | 0.39% |
ISCG | 26.95% | $633.06M | 0.06% |
PSC | 26.72% | $735.23M | 0.38% |
VBK | 26.68% | $19.49B | 0.07% |
ESML | 26.48% | $1.87B | 0.17% |
NUSC | 26.47% | $1.21B | 0.31% |